DR. PAUL CLIFFORD HERRMANN, M.D.
Medical Practice at Anderson St, Loma Linda, CA

2011030, Dec 8, 2011

Apr 25, 2011

13/093825

James P. Collman - Stanford CA, US
Paul Clifford Herrmann - Loma Linda CA, US
David Alvin Tyvoll - La Jolla CA, US
Richard Decreau - Cedex, FR
Brian Stanley Bull - Loma Linda CA, US
Christopher Jeffrey Barile - San Carlos CA, US

Stanford University - Palo Alto CA

A61K 31/4192, C07D 277/02, C07F 9/54, C07D 257/04, C07D 277/40, C07D 277/22, C07D 277/24, C07D 209/12, C07D 233/84, C07D 239/26, C07D 339/04, A61K 31/41, A61K 31/426, A61K 31/4164, A61K 31/404, A61K 31/505, A61K 31/385, A61P 7/02, A61P 9/10, A61P 9/04, A61P 3/00, A61P 9/12, A61P 3/10, A61P 9/00, C07D 249/06

514256, 548255, 548146, 548119, 548253, 548250, 548251, 548254, 548252, 5483241, 548199, 548202, 548203, 548491, 5483251, 544242, 549 39, 514359, 514381, 514370, 514365, 514392, 514415, 514398, 514440

It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.